**Figure S2. Assessment of Dose Proportionality for PBMC NHC-TP (A) AUC_{0-12} and (B) C_{max} on Day 11 Following Administration of Multiple Oral Doses of Molnupiravir Every 12 Hours for 10.5 Days in Healthy Participants (n = 6 for 400 mg, n = 6 for 600 mg, n = 12 for 800 mg)**

A

B

CI, confidence interval, NHC-TP, β-D-N4-hydroxycytidine triphosphate; PBMC, peripheral blood mononuclear cells

A true slope of 1.0 indicates perfect dose proportionality. Least-squares estimate and confidence interval from linear mixed-effects model including ln-dose as a continuous effect, performed on natural log-transformed values.